PMFA
ACRS icon

Plante Moran Financial Advisors’s Aclaris Therapeutics ACRS Stock Holding History

Plante Moran Financial Advisors’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-1,750
Closed -$31K – 805
2018
Q1 		$31K Buy
+1,750
New +$37.1K 0.02% 430

Other funds holding ACRS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Plante Moran Financial Advisors's ACRS Position: Q2 2018 in Review

Plante Moran Financial Advisors sold out of Aclaris Therapeutics (ACRS) in Q2 2018, closing a stake of 1,750 shares — an estimated $31K sold.

Plante Moran Financial Advisors first reported a position in ACRS in Q1 2018 and held it in 1 quarter. The position peaked at $31K in Q1 2018. 96 funds tracked by Wall St. Rank hold ACRS as of Q2 2018.

  • Plante Moran Financial Advisors reported no remaining Aclaris Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Plante Moran Financial Advisors sold 1,750 Aclaris Therapeutics shares in Q2 2018, an estimated $31K.
  • Plante Moran Financial Advisors first reported a position in Aclaris Therapeutics in Q1 2018 and held it in 1 quarter.
  • Plante Moran Financial Advisors's Aclaris Therapeutics position peaked at $31K in Q1 2018.
  • 96 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2018.

Based on Plante Moran Financial Advisors's 13F filing for Q2 2018, filed 26 Jul 2018.